Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

• ClinicalTrials.gov Identifier: NCT03534323
• Recruitment Status: Recruiting
• First Posted: May 23, 2018
• Last Update Posted: January 9, 2024
• Sponsor: Dana-Farber Cancer Institute
• Collaborator: Secura Bio, Inc.
• Information provided by (Responsible Party): Matthew S. Davids, MD, Dana-Farber Cancer Institute

Tracking Information

• First Submitted Date: May 2, 2018
• First Posted Date: May 23, 2018
• Last Update Posted Date: January 9, 2024
• Actual Study Start Date: July 12, 2018
• Estimated Primary Completion Date: July 1, 2024 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: May 11, 2018)

• Maximum Tolerated Dose of Venetoclax When Administered with Duvelisib [ Time Frame: Up to 7 weeks ]
  As assessed by protocol-specified DLT criteria (phase I)
• Rate of complete remission [ Time Frame: 2 years ]
  By IW-CLL criteria (phase II)

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: May 11, 2018)

• Cmax [ Time Frame: Up to 7 weeks ]
  Cmax
• Half-life [ Time Frame: Up to 7 weeks ]
  Half-life
• Volume of Distribution [ Time Frame: Up to 7 weeks ]
  Volume of Distribution
• Objective response rate [ Time Frame: 2 years ]
  By IW-CLL Criteria
• Duration of response [ Time Frame: 2 years ]
  By IW-CLL Criteria
• Progression free survival [ Time Frame: 2 years ]
  By IW-CLL Criteria
• Rate of minimal residual disease negativity [ Time Frame: 2 years ]
  By IW-CLL Criteria

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
• Official Title: A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients With Richter's Syndrome
• Brief Summary: This research study is assessing a new drug, duvelisib, in combination with a drug that is already FDA approved, venetoclax, as a possible treatment for participants with CLL or those with Richter's Syndrome

Detailed Description

This is a Phase I/II clinical trial. A Phase I clinical trial tests the safety of an investigational drugs and also tries to define the appropriate dose of the investigational drugs to use for further studies. "Investigational" means that the drugs are being studied together for the first time.

This phase I study tests the safety of the drug duvelisib when used in combination with the drug venetoclax. Duvelisib is still being studied, but the FDA (the U.S. Food and Drug Administration) has approved the use of Duvelisib in patients with CLL/SLL with relapsed or refractory CLL after having received 2 or more prior therapies.

Duvelisib is a drug that is given in capsule form and taken by mouth. This drug is designed to stop cancer growth by blocking a protein called phosphatidylinositide 3-kinase (PI3K), which is important for the survival of CLL cells. In laboratory studies and in other clinical trials that included participants with CLL, duvelisib was effective at killing CLL cells.

Venetoclax is a tablet that is taken by mouth. Venetoclax targets a protein called BCL-2, which helps cancer cells survive. Venetoclax is an effective treatment for many participants with CLL who do not respond to chemotherapy or other approved drugs or who have relapsed after prior therapy.Venetoclax is FDA approved for participants with CLL who have never had therapy before or whose CLL has worsened after prior therapy.

In the phase I portion of this study, the investigators are looking to determine the dose of venetoclax that is safe to give with duvelisib and to see what the side effects are of this combination.

In the phase II portion of this study, we are looking to determine how effective thecombination of duvelisib and venetoclax is for patients with CLL or Richter's Syndrome

• Study Type: Interventional
• Study Phase: Phase 1; Phase 2
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Chronic Lymphocytic Leukemia
• Richter Syndrome

Intervention

• Drug: Duvelisib
  This drug is designed to stop cancer growth by blocking a protein called phosphatidylinositide 3-kinase (PI3K), which is important for the survival of CLL cells.
  Other Name: IPI-145
• Drug: Venetoclax
  Venetoclax targets a protein called BCL-2, which helps cancer cells survive.
  Other Name: Venclexta

Study Arms

Experimental: Duvelisib +Venetoclax,

Duvelisib will be given alone for the first seven days. On day 8 Venetoclax will be added.

• Duvelisib will be administered orally twice daily
• Venetoclax will be administered orally daily
• All patients will be admitted for administration of the initial dose of venetoclax at each dose escalation

Interventions:

• Drug: Duvelisib
• Drug: Venetoclax

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: November 12, 2019): 67
• Original Estimated Enrollment (submitted: May 11, 2018): 47
• Estimated Study Completion Date: July 1, 2026
• Estimated Primary Completion Date: July 1, 2024 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Must have a confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma requiring therapy, as per IW-CLL 2008 criteria OR Biopsy proven transformation to diffuse large B cell lymphoma (DLBCL), consistent with Richter's Syndrome
• Disease that has progressed during or relapsed after at least one previous CLL/SLL therapy - If Richter's Syndrome, this criterion is not applicable
• Age greater to or equal to 18 years
• ECOG performance status ≤2 (Karnofsky ≥60%)

• Patients must meet the following hematologic criteria at screening, unless they have significant bone marrow involvement of CLL confirmed on biopsy:

  • Absolute neutrophil count ≥500 cells/mm3 (0.5 x 109/L). Growth factor is allowed in order to achieve this
  • Platelet count ≥25,000 cells/mm3 (25 x 109/L) independent of transfusion within 7 days of screening

• Adequate hepatic function defined as:

  --Serum aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x upper limit of normal (ULN), bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin

• Adequate renal function as defined as:

  --Serum creatinine ≤1.5 times the upper limit of normal or creatinine clearance ≥ 50 mL/min using a 24-hour urine collection

• Women of child-bearing potential and men must agree to use adequate contraception (hormonal, barrier method or abstinence) prior to study entry and for the duration of study participation
• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Previous treatment with venetoclax or duvelisib

• Patients receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, biologic therapy, surgery within 2 weeks of Cycle 1/Day 1 with the following exceptions:

  • For patients on targeted therapies, a washout of least five half lives is required
  • Patients who experience clinical deterioration may start therapy after a shorter washout period with prior approval by the PI
  • Corticosteroid therapy (prednisone or equivalent <20 mg daily) is allowed
• Confirmed central nervous system involvement
• Allogeneic hematologic stem cell transplant within 6 months of starting study treatment or active graft vs. host disease (GVHD) requiring treatment or prophylaxis
• History of active malignancy requiring therapy with the exception of hormonal therapy
• Any active systemic infection requiring IV antibiotics or uncontrolled, active infections
• Known history of human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV)
• Major surgery within 4 weeks of first dose of study drug
• Currently active gastrointestinal disease, including colitis, inflammatory bowel disease and diarrhea requiring therapy
• Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization
• Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk
• Use of Coumadin for anticoagulation (other anticoagulants permitted)
• Lactating or pregnant
• Concurrent administration of medications or foods that are strong inhibitors or inducers of CYP3A (see Appendix D) . The concomitant use of drugs or foods that are strong or moderate inhibitors or inducers of CYP3A are not allowed beginning 1 week prior to the first dose of duvelisib.
• Patients with ongoing use of prophylactic antibiotics are eligible as long as there is no evidence of active infection and the antibiotic is not included on the list of prohibited medications
• Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction resulting in malabsorption or chronic diarrhea
• Active abuse of alcohol
• History of chronic liver disease or veno-occlusive disease/sinusoidal obstruction syndrome
• History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function
• Known hypersensitivity to duvelisib and/or its excipients
• History of tuberculosis treatment within the 2 years prior to initiation of therapy

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Celeste Celeste; 857-215-1646; celeste_carey@dfci.harvard.edu

• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT03534323
• Other Study ID Numbers: 18-089
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Matthew S. Davids, MD, Dana-Farber Cancer Institute
• Original Responsible Party: Same as current
• Current Study Sponsor: Dana-Farber Cancer Institute
• Original Study Sponsor: Same as current
• Collaborators: Secura Bio, Inc.

Investigators

• Principal Investigator: Matthew S Davids, MD; Dana-Farber Cancer Institute

• PRS Account: Dana-Farber Cancer Institute
• Verification Date: January 2024